

AMENDMENTS TO THE CLAIMS

1-21. (canceled)

22. (original) A method of vaccinating an individual against stratum corneum chymotryptic enzyme, comprising the step of:

inoculating an individual with a stratum corneum chymotryptic enzyme protein or fragment thereof, wherein said stratum corneum chymotryptic enzyme protein or fragment thereof lack stratum corneum chymotryptic enzyme protease activity, wherein said inoculation with said stratum corneum chymotryptic enzyme protein or fragment thereof elicits an immune response in said individual, thereby vaccinating said individual against stratum corneum chymotryptic enzyme.

B |
1
23. (original) The method of claim 22, wherein said individual has a cancer, is suspected of having a cancer or is at risk of getting a cancer.

24. (original) The method of claim 22, wherein said stratum corneum chymotryptic enzyme fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment.

25. (original) The method of claim 24, wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 31, 32, 33, 34, 35, 36, 80, 86 and 99.

26. (original) A method of producing immune-activated cells directed toward stratum corneum chymotryptic enzyme, comprising the steps of:

B1
mf

exposing dendritic cells to a stratum corneum chymotryptic enzyme protein or fragment thereof, wherein said stratum corneum chymotryptic enzyme protein or fragment thereof lacks stratum corneum chymotryptic enzyme protease activity, wherein said exposure to said stratum corneum chymotryptic enzyme protein or fragment thereof activates said dendritic cells, thereby producing immune-activated cells directed toward stratum corneum chymotryptic enzyme.

27. (original) The method of claim 26, wherein said immune-activated cells are selected from the group consisting of B-cells, T-cells and dendrites.

28. (original) The method of claim 26, wherein said stratum corneum chymotryptic enzyme fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment.

29. (original) The method of claim 28, wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 31, 32, 33, 34, 35, 36, 80, 86 and 99.

B1
30. (original) The method of claim 26, wherein said dendritic cells are isolated from an individual prior to said exposure, wherein said activated dendritic cells are reintroduced into said individual subsequent to said exposure.

31. (original) The method of claim 30, wherein said individual has a cancer, is suspected of having a cancer or is at risk of getting a cancer.

32-39. (canceled)